Perindopril: a long-term certainty in treating hypertension

Česká verzia

Authors: Miroslav Souček
Authors place of work: II. interní klinika Fakultní nemocnice u sv. Anny v Brně a Lékařské fakulty Masarykovy univerzity, Brno
Published in the journal: Vnitř Lék 2021; 67(2): 119-124
Category:

Summary

Blockade of the renin angiotensin aldosterone system (RAAS) is currently considered to be the gold standard of antihypertensive therapy. ACE inhibitors and AT1-blockers are clinically the most relevant groups of RAAS blockers. Even though both drug groups block angiotensin II, ACE inhibitors typically reduce the degradation of bradykinin, which leads to the release of nitric oxide and prostaglandins with subsequent vasodilation. These differences in the mechanism of action can be of clinical relevance for hypertensive patients. Morbidity mortality studies of RAAS blockers have been reported in which ACE inhibitors, particularly perindopril, improved the overall survival in hypertensive patients. In the ONTARGET trial, a direct comparison of both drug groups yielded comparable results. Perindopril, which has been used in the clinical practice for more than 25 years, is a long-acting lipophilic angiotensin-converting enzyme inhibitor with a once-daily dosage schedule and a high affinity to tissue-converting enzyme. Its safety, efficacy, and very good tolerance have been shown in a number of studies. It is part of many fixed combinations which improve patient compliance and increase the effect of treatment of cardiovascular diseases.

Keywords:

hypertension – RAAS system – ACE inhibitors – AT1-blockers – fixed combination

Zdroje

1. Widimský J jr, Filipovský J, Ceral J et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze ČSH 2017. Hypertenze & kardiovaskulární prevence 2018; 7 (Suppl): 1– 22.

2. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–1357.

3. Van Vark L, Bertrand M et al. Angiotensin‑ converting enzyme inhibitors reduce mortality in hypertension: a meta‑analysis of randomized clinical trials of RAAS inhibitors involving 158 998 patients.Eur Heart J, 2012; 33: 2088–2097.

4. Dahlöf B, Sever PS, Poulter NE et al, for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo‑Scandinavian Cardiac Outcomes Trial‑Blood Pressure Lowering Arm (ASCOT‑BPLA). Lancet. 2005; 366: 895–906.

5. Beckett NS, Peters R, Fletcher AE et al. for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–1898.

6. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with Type 2 dibetes mellitus (the ADVANCE trial): a randomised controlled trial.Lancet 370,829-840(2007).

7. Cheng J, Zhang W, Zhang X et al. Effect of angiotensin‑converting enzyme inhibitors and angiotensin II receptor blockers on all‑ cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus. JAMA Intern Med 2014; 174: 773–785.

8. Ferrari R. Angiotensin‑ converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert rev Cardiovasc Ther 2005; 3: 15–29.

9. Ceconi C, Fox KM, Remme WJ et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study; PERTINENT. Cardiovasc Res 2007; 73: 237–246.

10. Ferrari R, Fox K. Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate „EUROPA“ story. Drugs 2009; 69: 265–277.

11. Cargnoni A, Comini L, Bernocchi P et al. Role of bradykinin and eNOS in the anti‑ischaemic effect of trandolapril. Br J Pharmacol 2001; 133: 145–153.

12. Unger T. Pharmacological properties of angiotensin II antagonists: examining all the therapeutic implications. J Renin Angiotensin Aldosterone Syst 2001; 2(Suppl.2): S4–7.

13. Ferrari R, Rosano GM. Nejen čísla, ale roky vědecké práce: meta‑analýzy porovnání ACE inhibitorů a AT1-blokátorů v kontextu. Int J Cardiology 2013; 166(2): 286–288.

14. Souček M. Účinek inhibitorů ACE a AT1-blokátorů na pokles celkové mortality u pacientů s hypertenzí, diabetes mellitus a bez srdečního selhání. Diabetologie, metabolismus, endokrinologie, výživa 2017 (20) 1: 7–14.

15. Mann JF, Anderson C, Gao P et al. Dual inhibition of the renin‑angiotensin systém in high‑risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J Hypertens 2013; 31: 141–421.

16. Hayek T, Hamoud S, Keidar S et al. Omapatrilat decreased macrophage oxidative status and atherosclerosis progression in atherosclerotic apolipoprotein E‑deficient mice. J Cardiovasc Pharmacol 2004; 43: 140–147.

17. Rodriguez -Granillo GA, Vos J, Bruining N et al. Long term effect of perindopril on coronary atherosclerosis progression (from the PERindopril’s Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation (PERSPECTIVE Study). Am J Cardiol 2007; 100: 159–163.

18. Vítovec J, Špinar J, Špinarová L. Perindopril a léčba kardiovaskulárních onemocnění aneb 25 let úspěšného působení perindoprilu v kardiologii. Kardiol Rev Int Med 2018; 20(3): 218–222.

19. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta‑analysis on 11,000 participants from 42 trials. Am J Medicine 2009; 122(3): 290– 300. doi: 10.1016/ j.amjmed.2008. 09. 038.

20. Bangalore S, Kamalakkannan G, Parkar S et al. Fixed‑dose combinations improve medication compliance: a meta‑analysis. Am J Med 2007; 120(8): 713– 719. doi: 10.1016/ j.amjmed. 2006. 08. 033.